TwinCell

TwinCell is a causal AI-powered virtual cell platform developed by DeepLife, a biotech company focused on curing disease at the cellular level through digital twins. Designed for early-stage drug discovery teams, TwinCell combines patient-derived single-cell data with causal AI to generate interpretable biological mechanisms — moving beyond opaque, correlational models to deliver actionable, mechanistically grounded insights.

Unlike conventional virtual cell approaches, TwinCell functions as a Large Causal Cell Model (LCCM) that traces how diseased cells can be driven back to healthy states. It is built for scientists and drug discovery professionals who need to identify novel targets, de-risk assets, and understand disease biology at cellular resolution — even without a deep bioinformatics background.

Core Differentiators

• Comprehensive data foundation: TwinCell is underpinned by over 1 billion harmonized single-cell multi-omics data points drawn from both public and proprietary sources, curated into unified atlases.
• Cell type-specific precision: The platform generates tailored interaction networks (interactomes) for every cell type, enabling accurate pathway discovery and precise condition modeling at cellular resolution.
• Causal AI-driven virtual cells: TwinCell ranks causal targets using traceback reasoning, ensuring predictions follow biologically plausible pathways and are both actionable and mechanistically interpretable.

Key Capabilities

• Cell-type specificity: Integrates public and proprietary multi-omics data into curated, harmonized atlases spanning diverse cell types implicated in disease, providing deep understanding of disease biology at cellular resolution.
• Interactome mapping: Generates cell-type-specific interaction networks using cutting-edge AI models, the world's largest omics database, and curated literature. Filters global networks to reveal disease-relevant pathways, eliminates noise, identifies robust biomarkers, and predicts drug effects on specific cell types to reduce off-target failures.
• Causal target identification: Combines single-cell embeddings with multi-omics networks to reveal key regulators driving cells from diseased to healthy states. Virtual cells test drug or gene perturbations in silico, outperforming traditional approaches in discovering new targets and identifying drug repositioning opportunities.

Use Cases: From Asset Strategy to Pipeline Confidence

• Find an indication for your asset: Prioritize, validate, and expand indications for an existing drug or target. Indications are ranked by network proximity, traced through mechanistic pathways, and validated at cellular resolution to surface where an asset is most likely to succeed.
• Find novel targets for a disease: Discover intervention points capable of reversing disease states using causal inference rather than correlation. Targets are ranked by predicted impact and grounded in biological rationale, revealing opportunities missed by existing research and conventional screens.
• Traceable, interpretable predictions: Every output is supported by traceable pathways and mechanistic reasoning, enabling teams to understand the cause of a disease state — not just its correlates.

What Users Are Saying

• Users highlight the platform's intuitive human interactome exploration and novel layout as unlike anything previously available.
• The enrichment analysis of network nodes has been called out as particularly valuable for biological interpretation.
• TwinCell has been praised as accessible and easy to use even for those without a bioinformatics background.

TwinCell is accessible via DeepLife's platform and is designed to integrate into early drug discovery workflows across target identification, indication finding, and mechanistic validation. DeepLife combines state-of-the-art multi-omics data, AI, and systems engineering to support pharmaceutical and biotech teams in building pipeline confidence from the earliest stages of discovery.